NO872659L - Farmastiske preparater med galaktitol som brer. - Google Patents
Farmastiske preparater med galaktitol som brer.Info
- Publication number
- NO872659L NO872659L NO872659A NO872659A NO872659L NO 872659 L NO872659 L NO 872659L NO 872659 A NO872659 A NO 872659A NO 872659 A NO872659 A NO 872659A NO 872659 L NO872659 L NO 872659L
- Authority
- NO
- Norway
- Prior art keywords
- galactitol
- weight
- parts
- water
- pharmaceuticals
- Prior art date
Links
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 102000008072 Lymphokines Human genes 0.000 abstract 1
- 108010074338 Lymphokines Proteins 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 150000008064 anhydrides Chemical class 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/879,143 US4797388A (en) | 1984-05-21 | 1986-06-26 | Pharmaceutical compositions with galactitol as carrier |
Publications (2)
Publication Number | Publication Date |
---|---|
NO872659D0 NO872659D0 (no) | 1987-06-25 |
NO872659L true NO872659L (no) | 1987-12-28 |
Family
ID=25373508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO872659A NO872659L (no) | 1986-06-26 | 1987-06-25 | Farmastiske preparater med galaktitol som brer. |
Country Status (9)
Country | Link |
---|---|
US (1) | US4797388A (no) |
EP (1) | EP0251657B1 (no) |
JP (1) | JPS6322527A (no) |
AT (1) | ATE68978T1 (no) |
AU (1) | AU599111B2 (no) |
DE (1) | DE3774192D1 (no) |
DK (1) | DK330787A (no) |
FI (1) | FI872831A (no) |
NO (1) | NO872659L (no) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2040394T3 (es) * | 1988-03-19 | 1993-10-16 | Asta Medica Aktiengesellschaft | Procedimiento para preparar un material liofilizado de ifosfamida y mesna. |
US5215743A (en) * | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
US5141925A (en) * | 1990-04-23 | 1992-08-25 | Trustees Of Tufts College | Vivo methods for treating coccidiosis |
GB2271281A (en) * | 1992-10-09 | 1994-04-13 | Orion Yhtymae Oy | Stabilised cyclophosphamide compositions |
US6794536B1 (en) | 1998-12-10 | 2004-09-21 | Aesqen, Inc. | Method for preparation of disodium pamidronate |
US6160165A (en) * | 1998-12-10 | 2000-12-12 | Aesgen, Inc. | Method for preparation of disodium pamidronate |
US7695736B2 (en) * | 2001-04-03 | 2010-04-13 | Pfizer Inc. | Reconstitutable parenteral composition |
CA2347330C (en) * | 2001-05-10 | 2002-03-12 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
US6613927B1 (en) | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
CN100375622C (zh) * | 2003-11-25 | 2008-03-19 | 范敏华 | 一种氟尿嘧啶冻干粉针剂及其制备方法 |
WO2006089002A2 (en) * | 2005-02-15 | 2006-08-24 | Yale University | Method for high throughput screening for antibodies and proteins inducing apoptosis |
US7989631B2 (en) * | 2006-02-10 | 2011-08-02 | Amgen Inc. | Hydrate forms of AMG706 |
US10149857B2 (en) | 2017-03-09 | 2018-12-11 | Ampac Fine Chemicals Llc | Lyophilized cyclophosphamide composition and methods of preparation thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1079397A (en) * | 1965-01-13 | 1967-08-16 | Chinoin Gyogyszer Es Vegyeszet | 1,6-dibromo-1,6-dideoxy dulcitol and pharmaceutical compositions containing it |
US3384546A (en) * | 1965-05-28 | 1968-05-21 | Miles Lab | Directly compressed low-density crystalline sorbitol pharmaceutical tablets |
US3944625A (en) * | 1973-02-02 | 1976-03-16 | Georgia-Pacific Corporation | Separation of mannitol from galactitol |
FI53651C (fi) * | 1976-06-24 | 1979-05-15 | Farmos Oy | Fodervitaminloesning eller -emulsion |
JPS5920647B2 (ja) * | 1976-10-01 | 1984-05-15 | 武田薬品工業株式会社 | 注射剤 |
JPS56127321A (en) * | 1980-03-10 | 1981-10-06 | Mochida Pharmaceut Co Ltd | Preparation of gamma-globulin pharmaceutical |
JPS5711909A (en) * | 1980-06-23 | 1982-01-21 | Shionogi & Co Ltd | Stable freeze-dried preparation of beta-lactam |
JPS5874617A (ja) * | 1981-10-28 | 1983-05-06 | Green Cross Corp:The | 人由来血液凝固第7因子含有水溶液の加熱処理方法 |
EP0080879B1 (en) * | 1981-11-28 | 1986-10-01 | Sunstar Kabushiki Kaisha | Pharmaceutical composition containing interferon in stable state |
IT1151126B (it) * | 1982-03-30 | 1986-12-17 | Pirelli | Procedimento e apparecchiatura per la fabbricazione di pneumatici |
US4537883A (en) * | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
JPH0651641B2 (ja) * | 1983-08-29 | 1994-07-06 | 株式会社ミドリ十字 | ガンマ・インターフェロン組成物 |
EP0133767B1 (en) * | 1983-08-04 | 1991-04-03 | The Green Cross Corporation | Gamma interferon composition |
US4659699A (en) * | 1983-08-22 | 1987-04-21 | Cetus-Ben Venue Therapeutics | Process for freeze drying cyclophosphamide |
JPS60190711A (ja) * | 1984-03-09 | 1985-09-28 | Tokyo Tanabe Co Ltd | プロトポルフイリン類注射用製剤 |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
EP0225581A3 (en) * | 1985-11-30 | 1989-05-24 | Green Cross Corporation | Method for the heat-treatment of immunoglobulins and immunoglobulin product |
-
1986
- 1986-06-26 US US06/879,143 patent/US4797388A/en not_active Expired - Fee Related
-
1987
- 1987-06-23 DE DE8787305579T patent/DE3774192D1/de not_active Expired - Lifetime
- 1987-06-23 AT AT87305579T patent/ATE68978T1/de active
- 1987-06-23 EP EP87305579A patent/EP0251657B1/en not_active Expired - Lifetime
- 1987-06-25 NO NO872659A patent/NO872659L/no unknown
- 1987-06-25 AU AU74702/87A patent/AU599111B2/en not_active Ceased
- 1987-06-26 FI FI872831A patent/FI872831A/fi not_active Application Discontinuation
- 1987-06-26 JP JP62157947A patent/JPS6322527A/ja active Pending
- 1987-06-26 DK DK330787A patent/DK330787A/da not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU7470287A (en) | 1988-01-07 |
EP0251657A2 (en) | 1988-01-07 |
NO872659D0 (no) | 1987-06-25 |
FI872831A0 (fi) | 1987-06-26 |
AU599111B2 (en) | 1990-07-12 |
DK330787D0 (da) | 1987-06-26 |
EP0251657A3 (en) | 1988-06-22 |
JPS6322527A (ja) | 1988-01-30 |
US4797388A (en) | 1989-01-10 |
EP0251657B1 (en) | 1991-10-30 |
ATE68978T1 (de) | 1991-11-15 |
DK330787A (da) | 1987-12-27 |
FI872831A (fi) | 1987-12-27 |
DE3774192D1 (de) | 1991-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0395329T4 (da) | Sammensætning i form af et skum indeholdende 5-aminosalicylsyre til intrarektal administration | |
FI872864A0 (fi) | Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi | |
NO872659L (no) | Farmastiske preparater med galaktitol som brer. | |
DE3688114D1 (de) | Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate. | |
ATE76747T1 (de) | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. | |
DE69223914D1 (de) | 4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate | |
ATE84032T1 (de) | Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate. | |
FR2679906B1 (fr) | Nouvelles (isoquinolein-5 yl) sulfonamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
MC2025A1 (fr) | Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee | |
PT89802A (pt) | Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas | |
ES2198424T3 (es) | Soluciones inyectables listas para el empleo que contienen doxorrubicina. | |
GR3002765T3 (en) | New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient | |
DE3866198D1 (de) | Pharmazeutische zubereitung fuer die intrarektale verabreichung von calcitonin und daraus hergestellte einzeldosisformen. | |
ES2036539T3 (es) | Un procedimiento para preparar derivados de ergolina. | |
ATE118033T1 (de) | Prourokinasederivate mit niedrigem molekulargewicht und sie enthaltende pharmazeutische zusammensetzungen. | |
ITMI911845A1 (it) | Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico. | |
ES2016052A6 (es) | Procedimiento para preparar derivados de adenosinmonofosfonato (amp) ciclico y de guanosinmonofosfonato (gmp) ciclico. | |
FI810643L (fi) | I 10-staellning substituerade 5-cyanmetylendibenzo /a d/ cyklohepten foerfarande foer deras framstaellning och terapeutiska medel innehaollande dem |